The initiation of coverage by Craig-Hallum with a Buy rating and a specific price target of $15 is a strong positive signal to the market, indicating a bullish outlook on Maravai LifeSciences by a reputable analyst. This can lead to increased investor confidence and potentially drive the stock price up in the short term.